- UroShield™ demonstrates 94% reduction in CAUTIs and catheter blockages.
- Significant 92% decrease in unplanned hospital visits.
- High patient satisfaction and compliance with prolonged intervals between catheter changes.
NanoVibronix, Inc. (NAOV, Financial), a company specializing in therapeutic medical devices, has announced positive results from a retrospective case series evaluating its UroShield™ system. Conducted from September 2023 to January 2025, the study involved patients using UroShield for periods ranging from 12 weeks to 17 months. Researchers from University Hospitals Coventry and Warwickshire Partnership NHS spearheaded the assessment, focusing on catheter-associated urinary tract infections (CAUTIs), catheter blockages, and hospital visits.
The study highlighted a remarkable 94% average reduction in CAUTIs and catheter blockages, alongside a 92% decrease in unplanned hospital visits. Patients experienced extended intervals between catheter changes, which notably enhanced their comfort and quality of life. The findings further corroborate previous research, underscoring the efficacy of UroShield in minimizing catheter-related risks and healthcare burdens.
According to Brian Murphy, CEO of NanoVibronix, Inc., these outcomes reinforce the mounting clinical evidence supporting UroShield as a beneficial solution for patients with long-term catheterization. UroShield employs proprietary Surface Acoustic Wave (SAW) technology to impede bacterial colonization on indwelling catheters, a significant advancement in mitigating complications such as CAUTIs.
The case series will be presented at the Association for Continence Professionals annual conference, ACP 2025, on May 19, 2025. For further details, visit the conference website.
